WEBWIRE – Friday, January 7, 2022
Mitsubishi Chemical Holdings Corporation (MCHC) hereby announces that its Board of Directors meeting today passed a resolution on personnel changes with regard to the Representative Corporate Executive Officer as detailed below.
1. Current and New Representative Corporate Executive Officers
New Position / Current Position / Name
Executive Vice President – Head of Petrochemical and Coal business / Representative Managing Corporate. Executive Officer, Supervising Corporate Strategy, Division, Corporate Communications. Office (Branding) / Yoshihiro Ikegawa
Representative Corporate Executive Officer, Executive Vice President, Chief Supply Chain Officer / Representative Director, Director of the Board, Managing Executive Officer, Supervising- Supply Chains, Mitsubishi Chemical Corporation /Nobuo Fukuda
2. Biography of the New Representative Corporate Executive Officer
Nobuo Fukuda – (Date of Birth: December 9, 1958 – Number of shares held: 21,074)
1981 Joined Mitsubishi Chemical Industries Limited (currently, Mitsubishi Chemical Corporation)
2012 General Manager, Kurosaki Plant, Mitsubishi Chemical Corporation
2014 Executive Officer, General Manager of Chemical Products, Mitsubishi Chemical Corporation
2021 Representative Director, Director of the Board, Managing Executive Officer supervising- Supply Chains, Mitsubishi Chemical Corporation (current position)
3. Scheduled Date of Personnel Changes
April 1, 2022
4. Reason for the Personnel Changes
Changes in the management structure
In its new management policy Forging the future announced on 1 December 2021, MCHC announced its management structure from 1 April 2022. For more details, please refer to the attached press release 4. Leaner Structure to Execute Strategy.
Corporate Executive Officers of MCHC from 1 April 2022 onwards is shown in the Annex.
Corporate Executive Officers (as of April 1, 2022)
Representative Corporate Executive Officer, President and Chief Executive Officer Jean-Marc Gilson Representative Corporate Executive Officer, Executive Vice President Chief Supply Chain Officer – Nobuo Fukuda
Executive Vice President, Chief Financial Officer Supervising finance, communication, IR and government affairs – Yuko Nakahira
Executive Vice President, Chief Compliance Officer General Counsel Supervising legal, internal control, admin, HR and corporate administration – Ken Fujiwara
Executive Vice President Head of Films & Molding Materials / Advanced Solutions Johei Takimoto Executive Vice President Head of Polymers & Compounds / MMA Hitoshi Sasaki Executive Vice President Head of Petrochemical & Coal business – Yoshihiro Ikegawa
Executive Vice President Head of Pharma Hiroaki Ueno Senior Vice President, Chief Technology Officer – Larry Meixner
Senior Vice President Supervising – government affairs – Shigeki Habuka
Corporate Executive Officers supervising digital and audit will be decided in due course
Eisai Co., Ltd. announced today that Biogen (Nasdaq: BIIB) has disclosed, in its Q1 2021 Earnings Press Release issued on April 22, its current submission status of the Marketing Authorization Applications (MAA) for aducanumab, an investigational treatment for Alzheimer’s disease, in countries other than the United States, Japan, and in Europe which have been announced previously.
In the first quarter of 2021 Biogen submitted a MAA to Ag?ncia Nacional de Vigil?ncia Sanit?ria (ANVISA) in Brazil for aducanumab an investigational treatment for Alzheimer’s disease. This application is currently in queue for review.
Biogen also submitted MAAs for aducanumab to Health Canada, the Therapeutic Goods Agency in Australia, and Swissmedic in Switzerland, all of which are subject to agency validation of whether the applications are accepted.
Aducanumab is being jointly developed by Biogen and Eisai.
Public Relations Department,
Eisai Co., Ltd.
Topic: Press release summary